Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 28, 2017

DrugPatentWatch Database Preview

Eletriptan hydrobromide - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for eletriptan hydrobromide and what is the scope of freedom to operate?

Eletriptan hydrobromide
is the generic ingredient in one branded drug marketed by Pfizer Ireland and is included in one NDA. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Eletriptan hydrobromide has one hundred and forty-seven patent family members in forty-six countries.

There are twelve drug master file entries for eletriptan hydrobromide. Five suppliers are listed for this compound. There are four tentative approvals for this compound.

Summary for Generic Name: eletriptan hydrobromide

Drug Master File Entries: see list12
Suppliers / Packagers: see list5
Bulk Api Vendors: see list30
Clinical Trials: see list16
Patent Applications: see list278
Drug Prices:see low prices
DailyMed Link:eletriptan hydrobromide at DailyMed

Pharmacology for Ingredient: eletriptan hydrobromide

Tentative approvals for ELETRIPTAN HYDROBROMIDE

Applicant Application No. Form Dosage
► Subscribe► SubscribeTABLET; ORAL20MG
► Subscribe► SubscribeTABLET; ORAL40MG
► Subscribe► SubscribeTABLET; ORALEQ 20MG BASE
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Ireland
eletriptan hydrobromide
TABLET;ORAL021016-001Dec 26, 2002RXYesNo5,545,644► SubscribeYY ► Subscribe
Pfizer Ireland
eletriptan hydrobromide
TABLET;ORAL021016-002Dec 26, 2002RXYesYes5,545,644► SubscribeYY ► Subscribe
Pfizer Ireland
eletriptan hydrobromide
TABLET;ORAL021016-002Dec 26, 2002RXYesYes6,110,940► Subscribe ► Subscribe
Pfizer Ireland
eletriptan hydrobromide
TABLET;ORAL021016-001Dec 26, 2002RXYesNo6,110,940► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Analyze global market entry opportunities
  • Formulary management
  • Set up watchlists for daily email updates

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus